335 related articles for article (PubMed ID: 19088170)
1. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma.
Ruan J; Hajjar K; Rafii S; Leonard JP
Ann Oncol; 2009 Mar; 20(3):413-24. PubMed ID: 19088170
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic therapies in non-Hodgkin's lymphoma.
Ruan J
Curr Cancer Drug Targets; 2011 Nov; 11(9):1030-43. PubMed ID: 21933106
[TBL] [Abstract][Full Text] [Related]
3. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma.
Ruan J; Hyjek E; Kermani P; Christos PJ; Hooper AT; Coleman M; Hempstead B; Leonard JP; Chadburn A; Rafii S
Clin Cancer Res; 2006 Oct; 12(19):5622-31. PubMed ID: 17020964
[TBL] [Abstract][Full Text] [Related]
4. B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy.
Jiang L; Li N
Angiogenesis; 2020 Nov; 23(4):515-529. PubMed ID: 32451774
[TBL] [Abstract][Full Text] [Related]
5. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
6. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
Song G; Li Y; Jiang G
Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis in malignant lymphoma.
Koster A; Raemaekers JM
Curr Opin Oncol; 2005 Nov; 17(6):611-6. PubMed ID: 16224242
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma.
Ho CL; Sheu LF; Li CY
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):316-21. PubMed ID: 12607599
[TBL] [Abstract][Full Text] [Related]
9. [Angiogenesis and hematologic malignancy].
Zini JM; Tobelem G
Bull Cancer; 2007 Jul; 94 Spec No():S241-6. PubMed ID: 17846010
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma.
Hazar B; Paydas S; Zorludemir S; Sahin B; Tuncer I
Leuk Lymphoma; 2003 Dec; 44(12):2089-93. PubMed ID: 14959852
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of angiogenesis inhibitors in hematologic malignancies.
Giles FJ
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):23-9. PubMed ID: 12102577
[TBL] [Abstract][Full Text] [Related]
14. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis and mast cells in non-Hodgkin's lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma.
Fukushima N; Satoh T; Sano M; Tokunaga O
Leuk Lymphoma; 2001 Aug; 42(4):709-20. PubMed ID: 11697501
[TBL] [Abstract][Full Text] [Related]
16. Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study.
Lattanzio R; La Sorda R; Facciolo F; Sioletic S; Lauriola L; Martucci R; Gallo E; Palmieri G; Evoli A; Alessandrini G; Ruco L; Rendina EA; Truini M; Chiarle R; Barreca A; Pich A; Ascani S; Remotti D; Tunesi G; Granone P; Ratto GB; Puma F; Pescarmona E; Piantelli M; Marino M; ; Carlini S; Cerasoli V; Corzani F; Melis E; Filippetti M; Canalini P; Palestro G; Lalle M; Ruffini E; Ceribelli A; Rinaldi M
Lung Cancer; 2014 Aug; 85(2):191-6. PubMed ID: 24908332
[TBL] [Abstract][Full Text] [Related]
17. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease.
Foss HD; Araujo I; Demel G; Klotzbach H; Hummel M; Stein H
J Pathol; 1997 Sep; 183(1):44-50. PubMed ID: 9370946
[TBL] [Abstract][Full Text] [Related]
18. The role of angiogenesis in human non-Hodgkin lymphomas.
Ribatti D; Nico B; Ranieri G; Specchia G; Vacca A
Neoplasia; 2013 Mar; 15(3):231-8. PubMed ID: 23479502
[TBL] [Abstract][Full Text] [Related]
19. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo.
Wang ES; Teruya-Feldstein J; Wu Y; Zhu Z; Hicklin DJ; Moore MA
Blood; 2004 Nov; 104(9):2893-902. PubMed ID: 15238424
[TBL] [Abstract][Full Text] [Related]
20. Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine.
Zhang C; Wang N; Tan HY; Guo W; Li S; Feng Y
Integr Cancer Ther; 2018 Sep; 17(3):582-601. PubMed ID: 29807443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
